Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2018
At a glance
- Drugs Bendamustine (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms PrE0403
- 19 Dec 2017 Planned End Date changed from 1 Jun 2022 to 1 Jul 2022.
- 19 Dec 2017 Planned primary completion date changed from 1 Nov 2021 to 1 Dec 2021.
- 19 Dec 2017 Status changed from not yet recruiting to recruiting.